Synta Will Sing A New Tune As Madrigal
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals Corp. will sing a new tune as Madrigal Pharmaceuticals Inc. after an all-stock reverse merger that will give Madrigal shareholders a 64% stake in the combined company, which will focus on cardiovascular, metabolic and liver diseases instead of Synta's failed cancer programs.
You may also be interested in...
Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.